Corvus Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Corvus Pharmaceuticals, Inc. on September 20, 2017. The Company is an emerging growth company incorporated in Delaware. The report discloses the entry into a material definitive agreement regarding an equity offering program.
Key Financial Metrics
This filing does not contain periodic financial statements, revenue, profit, cash flow, or margin data. The primary financial metric disclosed is the authorization of an "at the market" equity offering program with aggregate gross sales proceeds of up to $125,000,000.
Material Changes
On September 20, 2017, the Company entered into a Sales Agreement with Cowen and Company, LLC ("Cowen"). Under this agreement, Cowen will act as the sales agent to sell shares of the Company's common stock. The Company retains the right to set parameters for sales, including share quantity, timing, daily limits, and minimum price thresholds. The Company has no obligation to sell any shares and may suspend the program at any time.
Guidance, Outlook, and Risks
- Compensation: Cowen is entitled to compensation of up to 3.0% of the gross proceeds from shares sold under the agreement.
- Termination: Both the Company and Cowen may terminate the Sales Agreement at any time in their sole discretion upon written notice.
- Regulatory Status: Shares will be issued pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-217102). A prospectus supplement was filed with the SEC on September 20, 2017.
- Legal Opinion: A legal opinion from Latham & Watkins LLP regarding the shares is filed as an exhibit to this report.
Investor Verification Checklist
- Verify the current market price of Corvus Pharmaceuticals common stock to assess the potential dilution impact of the $125 million offering.
- Review the full Sales Agreement (Exhibit 1.1) for specific minimum price floors and daily sales volume limitations.
- Confirm the status of the Company's Form S-3 shelf registration statement (File No. 333-217102).
- Monitor future filings to determine if and when the Company elects to sell shares under this program.